1123620-89-2

Basic information

• Product Name: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid
• Synonyms: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid
• CAS NO: 1123620-89-2
• Molecular Formula: C₁₀H₉BrO₂
• Molecular Weight: 241.08126
• Mol File: 1123620-89-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 386.8 °C at 760 mmHg
• Flash Point: 166 °C
• Appearance: /
• Density: 1.05 g/cm³
• CAS DataBase Reference: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid(1123620-89-2)
• EPA Substance Registry System: (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid(1123620-89-2)

Safety Data

• Hazardous Substances Data: 1123620-89-2(Hazardous Substances Data)

Usage

General Description

The chemical "(1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid" is a compound with a cyclopropane ring that contains a carboxylic acid group and a bromophenyl substituent. It has a specific stereochemistry, with the two substituents on the cyclopropane ring in the "S" configuration. (1S,2S)-2-(4-broMophenyl)cyclopropanecarboxylic acid may have potential applications in pharmaceuticals or as a building block in organic synthesis due to its unique structure and reactivity. It is important to handle and use this compound with caution, following proper safety protocols and guidelines for handling chemical substances.

Upstream product

• 6142-65-0 trans-(1S,2S)/(1R,2R)-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 2137065-16-6 trans-2-(4-bromophenyl)cyclopropanecarboxylic acid 
• 875479-34-8 ethyl trans-2-(4-bromophenyl)cyclopropane-1-carboxylate 
• 4209-02-3 1-(4-bromophenyl)-2-chloroethan-1-one 
• 62566-68-1 (R)-2-(4-bromophenyl)oxirane 
• 1029431-48-8 (R)-1-(4-bromophenyl)-2-chloroethanol 
• 1332345-01-3 C₁₀H₉BrO₂*C₁₂H₁₃N 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 24393-53-1 ethyl (E)-3-(4-bromophenyl)-2-propenoate 
• 53582-00-6 ethyl trans-2-(p-bromophenyl)-1-cyclopropanecarboxylate 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 1240914-90-2 (1S,2S)-2-(4-cyano-phenyl)-cyclopropanecarboxylic acid 
• 1240914-95-7 ((1S,2S)-2-(4-bromophenyl)cyclopropyl)((R)-4-cyclobutyl-2-methylpiperazin-1-yl)methanone 
• 1119807-02-1 AZD₅₂₁₃ 
• 1240914-03-7 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide 
• 1241093-84-4 (1S, 2S)-2-(4-Carbamoyl-phenyl)-cyclopropanecarboxylic acid 
• 1240914-98-0 4-((1S, 2S)-2-((R)-4-cyclobutyl-2-methylpiperazine-1-carbonyl)cyclopropyl)benzonitrile 
• 1240914-92-4 C₁₁H₁₀NO₃^(1-)*Na⁽¹⁺⁾ 

Relevant articles and documents

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds displaying unexpected high CNS penetration. Increased MDCK efflux was utilized to identify compounds such as 33 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated. Differential activity was observed in GPR120 null and wild-type mice indicating that this effect operates through a mechanism involving GPR120 agonism.

Solid Forms Comprising A Cyclopropyl Amide Derivative

This disclosure relates to at least one solid form of 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide. This disclosure also relates to at least one pharmaceutical composition comprising at least one solid form described herein, methods of using the solid forms and pharmaceutical compositions comprised thereof, and processes of manufacturing the solid forms.

4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS

Compounds represented by Formula (I):or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognition.